CONFIDENTIAL The information contained in this document is regarded as confidential, and may not be disclosed to another party unless such disclosure is required to initiate the study, to conduct study -related activities, or to comply with national, state, or local laws and regulations. Written authorization from the coordinating site and sponsor is required for disclosure otherwise. PT-PhI-II v05.22.12 AVeRT: Anti-PD-1 monoclonal antibody (nivolumab) in combination with DC Vaccines for the Treatment of Recurrent Grade III and Grade IV Brain T umors Sponsor : PI – Duke Cancer Institute Funding Source: BMS and Departmental Funds Protocol Source: PI - Duke Cancer Institute Duke IRB#: Pro000 65241 IND#: 16301 Principal Investigator Katherine Peters , M.D., Ph.D. katherine.